Search Results

You are looking at 111 - 120 of 215 items for :

  • Refine by Access: All x
Clear All
Full access

Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma

Matthew Zibelman and Anthony J. Olszanski

, dysphagia, or dyspnea. He reported no significant weight loss, fevers, or chills, and had not noticed any other masses or unusual skin lesions. He did report mild fatigue. A brief trial of antibiotics was prescribed by a primary care physician but did not

Full access

Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition

Nisha Rao, Hans Iwenofu, Bingfeng Tang, Jennifer Woyach, and David A. Liebner

for <5% of all cases. 2 IMTs most often present with signs and symptoms restricted to the areas affected; however, 15% to 30% of people present with fever, weight loss, malaise, microcytic anemia, elevated erythrocyte sedimentation rate

Full access

NCCN News

who’ve been through the process already. The patient and family experience has been improved due to Moffitt’s nursing team’s efforts to provide dedicated education on the common side effects for CAR T-cell therapy, such as high fevers, neurotoxicity

Full access

Myeloid Growth Factors

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho

severe chronic neutropenia) based on a randomized controlled trial involving 123 patients. 109 In this study, daily treatment with subcutaneously administered G-CSF normalized neutrophils in most patients and prevented fever, mouth ulcers, and infections

Full access

Insights and Perspectives in the Clinical and Operational Management of Cancer-Related Anemia

Jennifer M. Hinkel, Edward C. Li, and Stephen L. Sherman

less than 20,000/μL for fever, sepsis, uncontrolled infections, a blood urea nitrogen of greater than 70, or veno-occlusive disease. One institution with a usual threshold of less than 10,000/μL increases this threshold to less than 20,000/μL for

Full access

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

, although they were not severe and were reversible. These reactions included mild myalgias, facial flushing, low-grade fever, headache, bone discomfort, nausea, and dyspnea. 106 A side-effect profile of GM-CSF, completed several years later, reported a

Full access

Non-Hodgkin’s Lymphomas, Version 1.2013

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, and Maoko Naganuma

65 years. Tumor flare reactions occurred in 71% of patients, but were grade 1 or 2 in nearly all cases. The most common grade 3 or 4 toxicity was neutropenia, which was reported in 49% of patients. Neutropenic fever occurred in 4 patients (6%). 24

Full access

Current Concepts in the Evaluation and Treatment of Patients With Diffuse Malignant Peritoneal Mesothelioma

Keli Turner, Sheelu Varghese, and H. Richard Alexander

symptoms are abdominal pain and increasing abdominal girth, the latter of which may be caused by ascites. 12 , 13 Weight loss and fever are other less-common presenting symptoms. 12 , 13 In some series, a palpable abdominal mass has been described on

Full access

Response Monitoring, Tolerability, and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner

myalgias, fatigue, fever, edema, and headache. Among patients experiencing an ADE, 10 (32%) had a dose reduction. The median time to dose reduction was 52 days, and the new median dose was 300 mg/d. A total of 6 patients (19%) discontinued imatinib because

Full access

The Role of Bridge Therapy Prior to Orthotopic Liver Transplantation

Meena A. Prasad and Laura M. Kulik

.4% vs 61.5%; P =.0493). 30 Table 2 Factors to Consider Before RFA Unfortunately, more than 50% of patients undergoing TACE develop symptoms of postembolization syndrome, consisting of abdominal pain, fever, nausea, and vomiting. In